AidaBreast® is a test that assesses the 10-year locoregional invasive breast cancer recurrence risk and predicts adjuvant treatment benefit.

Click to scroll preludedx dcisionrt logo subtle zebra 3d background subtle zebra 3d gray bg

PreludeDx has completed rigorous validations (analytical and clinical) of its novel, multi-omic invasive breast cancer test, AidaBreast®.

AidaBreast is now available. Please fill out the following form to be contacted.

Call 888-211-3247

The test results for each patient are the outcome of a risk algorithm that combines multi-omic protein and RNA biomarker expression to calculate an individualized score that aids in shared treatment decisions.